Catalyst Financial Partners LLC Raises Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Catalyst Financial Partners LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,631 shares of the medical research company’s stock after acquiring an additional 110 shares during the period. Catalyst Financial Partners LLC’s holdings in Thermo Fisher Scientific were worth $866,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in TMO. Raleigh Capital Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after buying an additional 27 shares during the period. Cedar Mountain Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 46 shares during the period. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $51,000. Financial Connections Group Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at $53,000. Finally, Operose Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 250.0% in the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after acquiring an additional 75 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of analyst reports. The Goldman Sachs Group lifted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. Barclays raised their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $607.35.

Thermo Fisher Scientific Trading Up 0.7 %

Shares of Thermo Fisher Scientific stock traded up $4.29 during trading hours on Thursday, reaching $577.93. 1,491,192 shares of the company’s stock were exchanged, compared to its average volume of 1,548,827. The firm has a market capitalization of $220.60 billion, a price-to-earnings ratio of 37.07, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80. The company has a fifty day moving average of $575.75 and a 200-day moving average of $535.39. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 37,711 shares of company stock valued at $21,630,972. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.